1
|
Alves AF, Vieira GC, Gadelha FAAF, Cavalcante-Silva LHA, Martins MA, Barbosa-Filho JM, Piuvezam MR. Milonine, an Alkaloid of Cissampelos sympodialis Eichl. (Menispermaceae) Inhibits Histamine Release of Activated Mast Cells. Inflammation 2018; 40:2118-2128. [PMID: 28812277 DOI: 10.1007/s10753-017-0652-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Milonine is an alkaloid of Cissampelos sympodialis Eichl. (Menispermaceae), a plant used in the northeast of Brazil to treat allergies such as asthma, rhinitis, and other conditions. Previously, several alkaloids were isolated from its roots and leaves with pharmacological properties in asthma and acute inflammation models. Therefore, the aim of this study was to evaluate the milonine effect on mast cells degranulation in vivo and in vitro. Swiss mice (n = 8) were used in models of paw edema induced by carrageenan, compound 48/80, or histamine. One hour before challenge, the animals were treated with milonine (at different doses) or standard drugs and, at different time points, the edema formation was measured. In addition, other different methods, such as anaphylactic shock reaction and scratching behavior models both induced by compound 48/80, a mast cell degranulator, were used to assess milonine effect histamine release in vivo. Moreover, milonine effect on mast cell degranulation in vitro was also carried out. Firstly, it was observed that milonine significantly decreased the carrageenan edema formation only at the beginning of the reaction (i.e., up to 2 h after challenge). Furthermore, this alkaloid decreased the edema induced by compound 48/80, maintained the paw tissue integrity, without modulating histamine-induced paw edema. In anaphylactic shock reaction, milonine increased the time of animal survival when compared with compound 48/80 group. Milonine also significantly decreased the scratching behavior induced by compound 48/80 with decreasing of mast cell degranulation in vitro. Therefore, these data indicated that milonine presents anti-allergic properties by decreasing mast cell degranulation rather than acting on histamine effect.
Collapse
Affiliation(s)
- Adriano Francisco Alves
- Laboratory of Immunopharmacology, Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil
| | - Giciane Carvalho Vieira
- Laboratory of Immunopharmacology, Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil
| | | | - Luiz Henrique Agra Cavalcante-Silva
- Laboratory of Immunopharmacology, Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil.,Postgraduate Program in Natural Products and Bioactive Synthetics (PgPNSB), Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil
| | | | - José Maria Barbosa-Filho
- Postgraduate Program in Natural Products and Bioactive Synthetics (PgPNSB), Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil
| | - Marcia Regina Piuvezam
- Laboratory of Immunopharmacology, Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil. .,Postgraduate Program in Natural Products and Bioactive Synthetics (PgPNSB), Health Sciences Centre, Federal University of Paraíba, João Pessoa, PB, Brazil.
| |
Collapse
|
2
|
Galvão JGFM, Cavalcante-Silva LHA, Carvalho DCM, Ferreira LKDP, Monteiro TM, Alves AF, Ferreira LAMP, Gadelha FAAF, Piuvezam MR, Rodrigues-Mascarenhas S. Author Correction: Ouabain attenuates ovalbumin-induced airway inflammation. Inflamm Res 2018; 67:277. [DOI: 10.1007/s00011-018-1130-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
3
|
Galvão JGFM, Cavalcante-Silva LHA, Carvalho DCM, Ferreira LKDP, Monteiro TM, Alves AF, Ferreira LAMP, Gadelha FAAF, Piuvezam MR, Rodrigues-Mascarenhas S. Ouabain attenuates ovalbumin-induced airway inflammation. Inflamm Res 2017; 66:1117-1130. [PMID: 28905075 DOI: 10.1007/s00011-017-1092-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 09/08/2017] [Accepted: 09/11/2017] [Indexed: 12/29/2022] Open
Abstract
PURPOSE Ouabain, an Na+/K+-ATPase inhibitor hormone, presents immunomodulatory actions, including anti-inflammatory effect on acute inflammation models. METHODS In the present study, the effect of ouabain in a model of allergic airway inflammation induced by ovalbumin (OVA) was assessed. RESULTS Initially, it was observed that ouabain treatment inhibited cellular migration induced by OVA on bronchoalveolar lavage fluid (BALF), mostly granulocytes, without modulating macrophage migration. In addition, it was observed, by flow cytometry, that ouabain reduces CD3high lymphocytes cells on BALF. Furthermore, treatment with ouabain decreased IL-4 and IL-13 levels on BALF. Ouabain also promoted pulmonary histological alterations, including decreased cell migration into peribronchiolar and perivascular areas, and reduced mucus production in bronchioles regions observed through hematoxylin-eosin (HE) and by periodic acid-Schiff stain, respectively. Allergic airway inflammation is characterized by high OVA-specific IgE serum titer. This parameter was also reduced by the treatment with ouabain. CONCLUSIONS Therefore, our data demonstrate that ouabain negatively modulates allergic airway inflammation induced by OVA.
Collapse
Affiliation(s)
- José Guilherme F M Galvão
- Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | | | - Deyse Cristina M Carvalho
- Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Laércia Karla D P Ferreira
- Laboratório de Imunofarmacologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Talissa Mozzini Monteiro
- Laboratório de Imunofarmacologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Adriano Francisco Alves
- Laboratório de Imunofarmacologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Larissa Adilis M P Ferreira
- Laboratório de Imunofarmacologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Francisco Allysson A F Gadelha
- Laboratório de Imunofarmacologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Marcia Regina Piuvezam
- Laboratório de Imunofarmacologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil
| | - Sandra Rodrigues-Mascarenhas
- Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba (UFPB), João Pessoa, Brazil.
| |
Collapse
|